Stromal cell-derived factor-1 as a potential therapeutic target for osteoarthritis and rheumatoid arthritis

Robert Bragg, William Gilbert, Ahmed M. Elmansi, Carlos M. Isales, Mark W. Hamrick, William D. Hill, Sadanand Fulzele

Research output: Contribution to journalReview article

Abstract

With age, joints become subject to chronic inflammatory processes that lead to degeneration of articular cartilage. Although multifactorial, cytokines have been shown to play a role in the pathogenesis of these chronic disease states. Stromal cell-derived factor 1 (SDF-1) is a chemokine that has been shown to be active in homeostatic mechanisms and developmental processes throughout the body, such as endochondral bone formation. SDF-1 plays a role in the transition from cartilage to bone. Although it has been shown to be a factor in normal development, it has also been shown to involve in the pathogenesis of rheumatoid arthritis (RA) and osteoarthritis (OA). In RA, SDF-1 has been shown to stimulate the recruitment of proinflammatory cells, as well as osteoclasts to the synovium, aiding in the facilitation of synovial degradation. Similarly, in OA, SDF-1 has been shown to regulate key proteins involved in the degradation of the cartilage of the joint. Because of its role in degenerative joint disease, SDF-1 has been investigated as a potential therapeutic target. Animal studies have been employing SDF-1 inhibitors, such as AMD3100 and T140, to study their effects on attenuating degenerative joint disease. These studies have shown promising results in slowing the progression of cartilage degradation and could potentially be used as therapeutic target for humans OA and RA.

Original languageEnglish (US)
JournalTherapeutic Advances in Chronic Disease
Volume10
DOIs
StatePublished - Jan 1 2019

Fingerprint

Chemokine CXCL12
Osteoarthritis
Rheumatoid Arthritis
Cartilage
Therapeutics
Joints
Synovial Membrane
Articular Cartilage
Osteoclasts
Chemokines
Osteogenesis
Chronic Disease
Cytokines
Bone and Bones
Proteins

Keywords

  • osteoarthritis
  • rheumatoid arthritis
  • stromal cell-derived factor-1 (SDF1)

ASJC Scopus subject areas

  • Medicine (miscellaneous)

Cite this

Stromal cell-derived factor-1 as a potential therapeutic target for osteoarthritis and rheumatoid arthritis. / Bragg, Robert; Gilbert, William; Elmansi, Ahmed M.; Isales, Carlos M.; Hamrick, Mark W.; Hill, William D.; Fulzele, Sadanand.

In: Therapeutic Advances in Chronic Disease, Vol. 10, 01.01.2019.

Research output: Contribution to journalReview article

@article{f26aca45516e4c148523f8909609612a,
title = "Stromal cell-derived factor-1 as a potential therapeutic target for osteoarthritis and rheumatoid arthritis",
abstract = "With age, joints become subject to chronic inflammatory processes that lead to degeneration of articular cartilage. Although multifactorial, cytokines have been shown to play a role in the pathogenesis of these chronic disease states. Stromal cell-derived factor 1 (SDF-1) is a chemokine that has been shown to be active in homeostatic mechanisms and developmental processes throughout the body, such as endochondral bone formation. SDF-1 plays a role in the transition from cartilage to bone. Although it has been shown to be a factor in normal development, it has also been shown to involve in the pathogenesis of rheumatoid arthritis (RA) and osteoarthritis (OA). In RA, SDF-1 has been shown to stimulate the recruitment of proinflammatory cells, as well as osteoclasts to the synovium, aiding in the facilitation of synovial degradation. Similarly, in OA, SDF-1 has been shown to regulate key proteins involved in the degradation of the cartilage of the joint. Because of its role in degenerative joint disease, SDF-1 has been investigated as a potential therapeutic target. Animal studies have been employing SDF-1 inhibitors, such as AMD3100 and T140, to study their effects on attenuating degenerative joint disease. These studies have shown promising results in slowing the progression of cartilage degradation and could potentially be used as therapeutic target for humans OA and RA.",
keywords = "osteoarthritis, rheumatoid arthritis, stromal cell-derived factor-1 (SDF1)",
author = "Robert Bragg and William Gilbert and Elmansi, {Ahmed M.} and Isales, {Carlos M.} and Hamrick, {Mark W.} and Hill, {William D.} and Sadanand Fulzele",
year = "2019",
month = "1",
day = "1",
doi = "10.1177/2040622319882531",
language = "English (US)",
volume = "10",
journal = "Therapeutic Advances in Chronic Disease",
issn = "2040-6223",
publisher = "SAGE Publications Inc.",

}

TY - JOUR

T1 - Stromal cell-derived factor-1 as a potential therapeutic target for osteoarthritis and rheumatoid arthritis

AU - Bragg, Robert

AU - Gilbert, William

AU - Elmansi, Ahmed M.

AU - Isales, Carlos M.

AU - Hamrick, Mark W.

AU - Hill, William D.

AU - Fulzele, Sadanand

PY - 2019/1/1

Y1 - 2019/1/1

N2 - With age, joints become subject to chronic inflammatory processes that lead to degeneration of articular cartilage. Although multifactorial, cytokines have been shown to play a role in the pathogenesis of these chronic disease states. Stromal cell-derived factor 1 (SDF-1) is a chemokine that has been shown to be active in homeostatic mechanisms and developmental processes throughout the body, such as endochondral bone formation. SDF-1 plays a role in the transition from cartilage to bone. Although it has been shown to be a factor in normal development, it has also been shown to involve in the pathogenesis of rheumatoid arthritis (RA) and osteoarthritis (OA). In RA, SDF-1 has been shown to stimulate the recruitment of proinflammatory cells, as well as osteoclasts to the synovium, aiding in the facilitation of synovial degradation. Similarly, in OA, SDF-1 has been shown to regulate key proteins involved in the degradation of the cartilage of the joint. Because of its role in degenerative joint disease, SDF-1 has been investigated as a potential therapeutic target. Animal studies have been employing SDF-1 inhibitors, such as AMD3100 and T140, to study their effects on attenuating degenerative joint disease. These studies have shown promising results in slowing the progression of cartilage degradation and could potentially be used as therapeutic target for humans OA and RA.

AB - With age, joints become subject to chronic inflammatory processes that lead to degeneration of articular cartilage. Although multifactorial, cytokines have been shown to play a role in the pathogenesis of these chronic disease states. Stromal cell-derived factor 1 (SDF-1) is a chemokine that has been shown to be active in homeostatic mechanisms and developmental processes throughout the body, such as endochondral bone formation. SDF-1 plays a role in the transition from cartilage to bone. Although it has been shown to be a factor in normal development, it has also been shown to involve in the pathogenesis of rheumatoid arthritis (RA) and osteoarthritis (OA). In RA, SDF-1 has been shown to stimulate the recruitment of proinflammatory cells, as well as osteoclasts to the synovium, aiding in the facilitation of synovial degradation. Similarly, in OA, SDF-1 has been shown to regulate key proteins involved in the degradation of the cartilage of the joint. Because of its role in degenerative joint disease, SDF-1 has been investigated as a potential therapeutic target. Animal studies have been employing SDF-1 inhibitors, such as AMD3100 and T140, to study their effects on attenuating degenerative joint disease. These studies have shown promising results in slowing the progression of cartilage degradation and could potentially be used as therapeutic target for humans OA and RA.

KW - osteoarthritis

KW - rheumatoid arthritis

KW - stromal cell-derived factor-1 (SDF1)

UR - http://www.scopus.com/inward/record.url?scp=85074132685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074132685&partnerID=8YFLogxK

U2 - 10.1177/2040622319882531

DO - 10.1177/2040622319882531

M3 - Review article

AN - SCOPUS:85074132685

VL - 10

JO - Therapeutic Advances in Chronic Disease

JF - Therapeutic Advances in Chronic Disease

SN - 2040-6223

ER -